NCT04347486View on ClinicalTrials.gov

Pharmacokinetic-pharmacodynamic Analysis of Sugammadex for Conventional Reversal in Children

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 29, 2020

Primary Completion Date

December 7, 2021

Study Completion Date

December 7, 2021

Conditions
Anesthesia, GeneralNeuromuscular Blockade
Interventions
DRUG

Sugammadex Injection 2mg/kg

Intravenous injection of 2mg/kg of sugammadex sodium on reappearance of T2

DRUG

Sugammadex Injection 4mg/kg

Intravenous injection of 4mg/kg of sugammadex sodium on reappearance of T2

DRUG

Sugammadex Injection 8mg/kg

Intravenous injection of 8mg/kg of sugammadex sodium on reappearance of T2

DRUG

Neuromuscular reversal agent injection

Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine

Trial Locations (1)

15710

SNUH, Seoul

All Listed Sponsors
collaborator

Ministry of Food and Drug Safety, Korea

OTHER_GOV

lead

Seoul National University Hospital

OTHER

NCT04347486 - Pharmacokinetic-pharmacodynamic Analysis of Sugammadex for Conventional Reversal in Children | Biotech Hunter | Biotech Hunter